Articles tagged with Prostate Cancer
A cancer therapy invented at Rice University has shown promising results in clinical trials, destroying tumors without debilitating side effects. Thirteen of the first 15 prostate cancer patients treated with AuroLase Therapy showed no detectable signs of cancer a year after treatment.
Researchers from Bern, Switzerland have been awarded major grants by the US Department of Defense to study new treatments for prostate cancer and develop methods to preserve severed limbs. The projects aim to identify factors driving metastasis and improve survival rates in prostate cancer patients.
A large population-based study found that novel oral androgen signaling inhibitor therapies increase the risk of death in patients with pre-existing cardiovascular conditions. Patients with three or more heart conditions experienced a 50% increase in mortality, while enzalutamide was associated with lower hospitalization rates.
A study found that chaperone protein Hsp70 inhibits toxic protein aggregates in the androgen receptor, which causes Kennedy's disease and prostate cancer. Hsp70 may be useful as a therapeutic target to treat these conditions.
As people age, the prostate grows, leading to an increased risk for prostate cancer and benign prostatic hyperplasia. A new UCLA study found that older mice have more luminal progenitor cells, which can generate new prostate tissue, helping explain why the prostate tends to grow with age.
The study found that adjuvant radiotherapy improved disease-free period for patients with locally advanced prostate cancer, with 82% of patients in the treatment group remaining disease-free. However, the treatment did not significantly impact survival rates.
Researchers at UVA have identified Hullk, a non-coding RNA that regulates biological processes in cells. The discovery offers potential for targeting and stopping prostate cancer progression with fewer side effects.
Scientists at MD Anderson Cancer Center found that PRC1 regulates metastasis by suppressing the immune system, leading to tumor blood vessel growth. A novel PRC1 inhibitor showed efficacy as a single treatment and cooperated with immunotherapy to suppress metastasis.
A Penn study of over 150,000 men with prostate cancer found that hormone therapy increased the likelihood of developing Alzheimer's disease or dementia. The treatment was associated with a 14% increased risk of Alzheimer's and a 20% increased risk of dementia compared to patients who did not receive hormone therapy.
A study of 154,089 older men diagnosed with prostate cancer found that androgen deprivation therapy increased the likelihood of being diagnosed with Alzheimer disease or dementia. The therapy was associated with a higher risk over an average follow-up period of eight years.
Researchers identify DNA-PK as a master regulator of gene networks promoting aggressive prostate cancer behaviors. A clinical trial combining standard-of-care with a first-in-man DNA-PK inhibitor shows promising early results.
A new study from the University of Pennsylvania finds that proton therapy can be as effective and safe as traditional treatments when administered in higher doses over a shorter period. The research, which included 184 men with non-metastatic prostate cancer, showed low rates of serious gastrointestinal and urologic issues.
A new biomarker in urine helps detect aggressive prostate cancer, improving detection accuracy and reducing unnecessary treatments. The noninvasive test was found to accurately identify high-risk individuals and achieved similar accuracy as invasive tissue-based tests.
The study identified three ways in which the FOXA1 gene mutates to trigger prostate cancer: FAST, FURIOUS, and LOUD. Class 1 mutations cause rapid DNA traversal, class 2 mutations prevent normal FOXA1 from binding, and class 3 mutations create duplications of oncogenes. These alterations have different clinical implications for patients.
Researchers developed a urine test called 'PUR' that can diagnose aggressive prostate cancer and predict treatment needs up to five years earlier than standard methods. The test identified men who are up to eight times less likely to require treatment within five years of diagnosis.
A novel combination therapy using two targeted treatments has shown to maximize efficacy while reducing side effects in men with progressive prostate cancer. The study found that nearly 70 percent of patients saw a more than 50 percent reduction in PSA levels after the treatment.
Research shows that adding an interim scan during therapy can help guide patient treatment, predicting survival and tumor response. Interim scans using PSMA PET imaging have shown significant predictive value for overall survival in patients undergoing 177Lu-PSMA radioligand therapy.
Inflammatory and immune-regulatory mechanisms were altered in animal models and prostate cancer tumor samples of WTC responders. These findings suggest that exposure to World Trade Center dust may contribute to chronic inflammation, which can drive prostate cancer progression.
A study by Mount Sinai researchers found that World Trade Center responders with prostate cancer exhibited chronic inflammation in their prostates, which may have contributed to their cancer. The researchers suggest that this link could lead to the development of anti-inflammatory therapies for similar cases.
A new study found that the protein CCN3 is a key factor promoting prostate cancer invasion of bone and predicting poor outcomes. High CCN3 expression correlated with shortened overall survival and bone metastases, while low-expression groups had better survival rates.
Researchers at UCLA Health Sciences have developed a more effective method for detecting prostate cancer by combining biopsy strategies. The new approach, which includes MRI-guided biopsy, increased the rate of cancer detection to up to 33% compared to traditional methods.
A new study by University of Surrey researchers found that community pharmacy interventions significantly improved physical activity levels and reduced weight, BMI, and cholesterol in men with prostate cancer. These lifestyle changes also led to increased grip strength and better overall fitness.
A prospective study found that higher levels of abdominal and thigh fat are associated with an increased risk of aggressive prostate cancer. Men with a lower BMI showed a stronger association between visceral fat and advanced prostate cancer. Lifestyle interventions, such as diet and exercise, may also reduce the risk of prostate cancer.
A study found that only 15% of men in North Carolina with low or intermediate-risk prostate cancer who chose active surveillance followed recommended monitoring guidelines. This suggests that patients may not be adhering to the guidelines, which include regular PSA tests and biopsies. The study's authors call for further research into ...
Researchers at Duke University Medical Center discovered how prostate cancer cells develop to mimic bone-forming cells, enabling proliferation in the bone microenvironment. This understanding could lead to more effective use of radium-233 and development of new therapies to treat or prevent prostate cancer spread to bone.
A new study found that black men with low-risk prostate cancer are 16% less likely to adopt active surveillance than non-black men, despite similar rates of overall active surveillance. The disparity is attributed to socioeconomic and insurance barriers that deter black patients from accessing follow-up care.
A new device forces cells through tiny channels, detecting blebbing in cancer cells to identify metastatic prostate cancer. Highly metastatic cells exhibit more blebbing than normal or less-metastatic cells.
Researchers at Boston University School of Medicine have discovered that inhibiting the BRD4 protein can consistently regulate prostate cancer cell migration and invasion. The study provides promising insights into preventing the spread of castration-resistant prostate cancer (CRPC), a highly aggressive form of the disease.
Researchers have identified a promising therapeutic target for metastatic prostate cancer by inhibiting the PHLPP2 protein, which stabilizes the oncogenic protein MYC. This finding has implications for treating other cancers driven by MYC and could lead to efficient new drugs.
Researchers discovered that blocking PHLPP2 enzyme halts prostate cancer growth and metastasis without signs of toxicity in mice or human cells. This finding presents a promising approach for treating prostate cancer and potentially other types of cancers.
The Damon Runyon Physician-Scientist Training Award provides physicians with research skills and experience to become leaders in translational and clinical research. The award addresses financial burdens that deter physicians from pursuing a research career, offering up to $460,000 over four years.
Researchers found higher levels of aneuploidy lead to greater lethality risk among prostate cancer patients, suggesting a possible way to predict prognosis and inform treatment. The study also identified chromosomes 7 and 8 as commonly aneuploid in prostate tumors.
Abnormal chromosome number abnormalities are linked to increased risk of lethal disease in prostate cancer patients. Patients with five or more predicted aneuploidy alterations had a 5.3 times higher odds of lethal cancer during follow-up.
A new study published in the Journal of Urology found that transperineal prostate biopsies (TPBx) under local anesthetic are the safest method for testing and diagnosing prostate cancer, with fewer complications and improved patient tolerability.
Researchers discovered that low levels of syntaphilin at the central core of prostate tumors correlate with increased risk of metastasis. The biomarker may identify patients who require more aggressive management and treatment.
Research reveals men treated for benign prostatic hyperplasia (BPH) with 5-α-reductase inhibitors experienced a two-year delay in prostate cancer diagnosis and were twice as likely to have advanced disease. PSA suppression from these medications led to delays in diagnosis, potentially resulting in worsened clinical outcomes.
A new imaging technique using subharmonic contrast-enhanced ultrasound may help detect prostate cancer in patients where MRI is negative. The study, to be presented at the ARRS Annual Meeting, found that the technique detected PCa in 9 of 31 patients with a prior negative MRI or biopsy.
A study of 429 men with metastatic castration-resistant prostate cancer found correlations between specific genetic alterations and clinical outcomes. The loss of the RB1 tumor suppressor gene was significantly correlated with poor survival in patients treated with androgen receptor signaling inhibitors.
Researchers have identified a gene mutation in prostate cancer that is linked to poor survival and increased relapse rates. The study found that men with this mutation are more than three times as likely to die and nearly seven times as likely to relapse on standard treatments.
Researchers at Karolinska Institutet have identified blood-based biomarkers that can determine which patients with advanced prostate cancer will benefit from continued hormonal therapy. The study suggests that patients with a normal TP53 gene and fewer AR resistance markers may benefit more from treatment.
A single high-dose treatment has shown promise in treating men with low-risk prostate cancer, reducing the need for multiple visits to the hospital. After two years, 94% of patients showed no sign of cancer returning, while those with medium-risk cancer saw a 95% success rate.
Research by UBC's Men's Health Research Program reveals that many men struggle with understanding prostate cancer diagnosis and treatment options. The study highlights the importance of health literacy in making informed decisions and managing personal health.
A recent UBC study found that a 'reduced workload' program is the best option for men recovering from a radical prostatectomy, reducing the risk of burnout and promoting full recovery. The researchers recommend that patients have an open conversation with their employer before surgery to come up with a plan for a gradual return to work.
Global prostate cancer incidence and mortality rates are decreasing or stabilizing, with the US experiencing a significant decline. The study highlights improvements in detection practices and treatment, but notes that PSA screening may contribute to diagnosis at later stages and higher mortality rates.
Researchers at the University of Bradford discovered a protein, EN2, released by cancer cells that alters normal cell behavior, promoting tumour growth and evading the immune system. The study found that both cancer and normal cells take up the protein, leading to changes in shape or fusion, allowing cancer cells to reactivate and spread.
Researchers from University of Texas Medical Branch at Galveston developed a laser treatment that selectively destroys cancerous prostate tissue while preserving erectile and urinary functions. This technique is shown to be as effective as complete removal or radiation therapy with improved quality of life.
Researchers at University of Alabama at Birmingham discovered androgen receptor imports into mitochondria, where it regulates multiple mitochondrial processes. This finding may lead to new treatment targets for castration-resistant prostate cancer.
Scientists have identified two coffee compounds, kahweol acetate and cafestol, which inhibit the growth of prostate cancer cells in cell culture and animal models. The study's findings suggest that these compounds may be used to treat drug-resistant prostate cancer, with further investigation needed.
Researchers found that men with high neuroticism are more likely to experience adverse events after prostate cancer surgery, such as erectile dysfunction and incontinence. The study suggests that personality tests may be a valuable tool for identifying at-risk patients and improving care.
A new web tool, PREDICT Prostate, helps patients make informed decisions about treatment for early prostate cancer by providing a personalized prognosis and treatment options. The tool uses data from over 10,000 UK men to estimate survival rates and potential side effects of treatment.
A new risk model developed by researchers can predict the survival of non-metastatic prostate cancer patients and the effect of different treatment approaches on survival. The PREDICT Prostate model uses data from over 10,000 men diagnosed with non-metastatic prostate cancer and has been validated in an external cohort.
The NRG Oncology trial suggests adding docetaxel-based chemotherapy to standard treatment should be considered for men with high-risk prostate cancer. The study found improved overall survival, disease-free survival, and reduced rates of distant metastases.
Scientists from Sanford Burnham Prebys Medical Discovery Institute identified how prostate cancer becomes treatment-resistant NEPC following targeted treatment. They found that an FDA-approved drug holds potential as a NEPC treatment and uncovered new therapeutic avenues to prevent transformation.
A phase III trial found hypofractionated radiotherapy (H-RT) to have similar QOL outcomes as conventional radiotherapy (C-RT) in men with low risk prostate cancer. H-RT delivers a total dose over a shorter period, reducing treatment duration and potential side effects.
Use of active surveillance for low-risk localized prostate cancer increased significantly between 2010 and 2015, becoming the dominant management strategy. Surgery rates declined among men with low-risk disease, while increasing in high-risk patients.
The use of active surveillance for low-risk prostate cancer nearly tripled between 2010 and 2015, with 42.1% of men adopting this strategy. This increase is associated with a favorable prognosis and reduced toxicity from treatment.
A new UCLA-led study shows that men with low- or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period and still have the same successful outcomes as from a much longer course of treatment. The study analyzed data from 2,142 men treated with stereotactic body radiotherapy for...
A new machine-learning framework distinguishes between low- and high-risk prostate cancer with higher precision than existing tools. The framework aims to provide radiologists and clinicians with a sound prediction tool for personalized patient care.
A new study suggests that enlarged prostates could impede tumor growth in prostate cancer patients. Computer simulations found that the mechanical stresses from an enlarging prostate keep tumors small. The findings challenge traditional treatments that involve downsizing the prostate.
Researchers at the University of Seville have characterized the normal electrical activity in PC-3 prostate cancer cells, showing a low-frequency pattern between 0.1 and 10 Hz. This study aims to explore the relationship between electrical patterns and cell proliferation, with potential applications for medicine delivery.